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Abstract
Background: Cell salvage is commonly used as part of a blood conservation strategy. However concerns among clinicians exist
about the efﬁcacy of transfusion of washed cell salvage.
Methods:We performed a meta-analysis of randomized controlled trials in which patients, scheduled for all types of surgery,
were randomized to washed cell salvage or to a control group with no cell salvage. Data were independently extracted, risk
ratio (RR), and weighted mean differences (WMD) with 95% conﬁdence intervals (CIs) were calculated. Data were pooled
using a random effects model. The primary endpoint was the number of patients exposed to allogeneic red blood cell (RBC)
transfusion.
Results:Out of 1140 search results, a total of 47 trials were included. Overall, the use of washed cell salvage reduced the rate of
exposure to allogeneic RBC transfusion by a relative 39% (RR=0.61; 95% CI 0.57 to 0.65; P<0.001), resulting in an average saving
of 0.20 units of allogeneic RBC per patient (weightedmean differences [WMD]=0.20; 95%CI0.22 to0.18; P<0.001), reduced
risk of infection by 28% (RR=0.72; 95%CI 0.54 to 0.97; P=0.03), reduced length of hospital stay by 2.31 days (WMD=2.31; 95%
CI2.50 to2.11; P<0.001), but did not signiﬁcantly affect risk of mortality (RR=0.92; 95%CI 0.63 to 1.34; P=0.66). No statistical
difference could be observed in the number of patients exposed to re-operation, plasma, platelets, or rate of myocardial infarction
and stroke.
Conclusions:Washed cell salvage is efﬁcacious in reducing the need for allogeneic RBC transfusion and risk of infection in surgery.
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Abbreviations: CIs= conﬁdence intervals, Hb= hemoglobin, PBM= patient bloodmanagement, RBC= red blood cell, RR= risk
ratio, WMD = weighted mean differences.
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1. Introduction
Allogeneic blood products can be lifesaving in many conditions
but limited in supply. However, inappropriate use of allogeneic
red blood cell (RBC) transfusion may even be associated with
increased risk of adverse outcome.[1–4] Patient blood manage-
ment (PBM) is a proactive, patient-centered, and multidisciplin-
ary approach to manage anemia, optimize hemostasis, minimize
iatrogenic blood loss, and harness tolerance to anemia. Overall
the concept aims to improve patient outcome by promoting and
preserving body’s own blood source. Cell salvage is used as part
of a blood conservation strategy, and covers a wide range of
techniques that scavenge blood from the operative ﬁeld and
wound drainages and re-infuse washed autologous RBCs back
into the patient. With advances in washing and ﬁltration
technology, new cell salvage devices now provide a high quality
blood product for re-infusion. The latest updated Cochranemeta-
analysis was published in 2010 and included 75 trials with
washed and unwashed cell salvage suggesting that cell salvage is
efﬁcacious in reducing the need for allogeneic RBC transfusion in
adult elective cardiac,vascular and orthopedic surgery.[5]
Here, we examined the overall efﬁcacy of washed cell salvage
in different ﬁelds of surgery by performing an updated systematic
review and meta-analysis of recent published randomized
controlled trials.
2. Material and methods
2.1. Registration
The presented study has been registered at PROSPERO
register (www.crd.york.ac.uk/PROSPERO, registration number:
CRD42016035726).
2.2. Population and intervention
Potentially eligible trials had to be prospective and randomized
including surgical patients. Patients in the intervention group
received intra- and/or postoperatively washed cell salvage (=cell
salvage group) whereas control patients received no cell salvage
(=control group). There was neither a limit of age nor type of
surgery.
2.3. Search methods for identiﬁcation of studies
We undertook a systematic search of the literature to identify
published reports, which investigated surgical patients receiving
either cell salvage or no cell salvage. We searched Medline using
the search terms “cell salvage” or “auto transfusion” or
“autologous blood transfusion” or “blood salvage” or “cell
saver” or “reinfusion system” and “blood transfusion” or
“hemorrhage” or “anesthesia” or “transfusion” or “bleeding” or
“blood loss” or “hemorrhage” and “randomized controlled
trial” or “controlled clinical trial” or “randomized controlled
trials” or “random allocation” or “double blind method” or
“single blind method” and “humans” not including “stem cell”.
A total of 954 Medline articles were identiﬁed and the abstracts
were searched for reference to mortality and relevant topic.
Additionally, we searched Cochrane Library using the same
search criteria and found 181 articles. We also hand-searched
grey literature and reference lists of identiﬁed articles and
included 5 studies additionally.
Two independent authors screened the abstracts of identiﬁed
studies (AW, PM). Discrepancies between the two reviewers were
resolved through consensus by discussion with a third reviewer
(SC). To be eligible for inclusion, studies had to include patients
undergoing surgery randomized to cell salvage or to a control
group that did not receive cell salvage. Study reports had to
provide data either on the number of patients transfused with red
cells or the volume of blood transfused. Transfusion data
expressed in milliliters were converted to units by dividing by
300. Flow chart and exclusion criteria are displayed in Fig. 1.
2.4. Risk of bias assessment
To determine the validity of the included trials, we assessed the
risk of bias including the domains of random sequence
generation, allocation concealment, blinding, incomplete out-
come data, and selective outcome reporting. If one or more
domains were judged as being high or unclear, we classiﬁed the
trial as having a “high risk of bias.”More details are provided in
the Supplemental Digital Content 1–3, http://links.lww.com/MD/
B173.
2.5. Endpoints
The primary endpoint of the systematic reviewwas the number of
patients exposed to allogeneic RBC transfusion. Secondary
endpoints were number of units of allogeneic blood transfused,
the number of patients exposed to re-operation for bleeding,
number of exposed patients to plasma, number of exposed
patients to platelets, infectious complications (pneumonia,
wound infection, or/and sepsis), myocardial infarction, stroke,
mortality, and length of hospital stay.
2.6. Ethical review
No personal data of patients were used in the present study. We
only used published statistical data of meta-analysis and
therefore ethical approval was not applicable in the current
meta-analysis.
2.7. Statistical analysis
The meta-analysis was done in line with recommendations from
the Preferred Reporting Items for Systemic reviews and Meta-
Analyses (PRISMA statement).[6] In addition, we used the
AMSTAR checklist in terms of the adequacy of conducting this
review.[7] All analyses and graphical illustrations were conducted
with Review Manager 5.3. for MAC (Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2012), and with
the R (A language and environment for statistical computing.
R Foundation for Statistical Computing, Vienna, Austria) using
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package meta of Guido Schwarzer (version 1.6–1) for assessing
publication bias. Risk ratio (RR) and 95% conﬁdence intervals
(95% CI) were calculated using the ﬁxed effects model
(DerSimonian and Laird estimator).[8] RRs were undeﬁned and
excluded for studies with no event in either arm.
Dichotomous and continuous data were pooled across trials
using a random effects model. The presence of heterogeneity and
comparisons of subgroups of trials was tested by Q-test, the x2
statistic as well as the I2 statistic. To ﬁnd a possible evidence for
publication bias, funnel plots of the RR were generated. We
considered P<0.05 to be statistically signiﬁcant. Subgroups were
prospectively deﬁned according to type of surgery (orthopedic,
cardiac, vascular, multiple trauma/massive transfusion, cancer,
gynecology/obstetric, and pediatric) and age (pediatrics/adults) to
determine whether effect sizes varied according to the type of
surgery.
3. Results
3.1. Study selection
Cross searching of electronic databases yielded a total of 1140
reports that met our inclusion criteria. After screening of all
abstracts, 137 reports were considered for full-text review. After
excluding of 90 additional reports, 47 studies[9–55] were
considered for ﬁnal quality analysis (Fig. 1, Table 1).
3.2. All types of surgery
Of the 47 trials, 15 included orthopedic
surgery,[12,17,18,24–27,30,38,40,42,44,48,54,55] 21 cardiac
surgery,[9,14–16,20,22,23,28,29,32,33,35–37,41,43,46,47,50,51,53] 6 vascu-
lar surgery,[13,19,31,45,49,52] 1 multiple trauma surgery,[10] 2
cancer surgery,[21,39] and 2 pediatric surgery.[11,34]
Thirty-six trials[9,10,12–16,18–24,26–28,30–34,36,38,41–46,48,50,52–55]
reported data on the number of subjects exposed to allogeneic
RBC transfusion. These trials included a total of 3433 patients of
whom 1783 were randomized to cell salvage. Overall, the use of
cell salvage reduced the rate of exposure to allogeneic RBC
transfusion by a relative 39% (RR=0.61; 95% CI 0.57 to 0.65;
P<0.001). Heterogeneity between these trials was statistically
signiﬁcant (P<0.001, I2=87%) (Fig. 2A). Thirty-ﬁve
studies[9–11,13–25,27,28,30,32–37,39,40,42,46,50–55] including 3027
patients analyzed the number of allogeneic RBC units per
patient. Comparison of 1625 patients using cell salvage with
1402 control patients resulted in an average saving of 0.20 units
per patient (WMD=0.20; 95% CI 0.22 to 0.18; P<0.001)
(Fig. 2B). Twenty eight percent less infection were observed in
908 patients with cell salvage comparedwith 990 control patients
(RR=0.72; 95% CI 0.54 to 0.97; P=
0.03)[10,11,13,16,19,20,22,27,28,31–33,38,42,43,45,48,49] (Fig. 2C). Mor-
tality was assessed in 22
studies[9–11,13,15,16,19,20,22,31–33,35,36,41,45,46,48–52] with a follow-
up of 24hours,[51] hospital stay[9,11,16,31–33,35,36,41,49,52] and 3
years,[48,50] while 8 trials[10,13,15,19,20,22,45,46] did not report time
for follow-up. No statistical difference could be observed in
mortality (RR=0.92; 95% CI 0.63 to 1.34; P=0.66; Fig. 2D),
the number of patients exposed to re-operation (RR=1.13; 95%
CI 0.70 to 1.81; P=0.62), plasma (RR=1.01; 95% CI 0.78 to
1.29; P=0.97), platelets (RR=0.82; 95% CI 0.62 to 1.09; P=
0.16), event rate of myocardial infarction (RR=0.76; 95% CI
0.47 to 1.24; P=0.27), and stroke (RR=0.64; 95% CI 0.30 to
1.37; P=0.25). However, length of hospital stay was reduced by
2.31 days in the cell salvage group compared with the control
group (WMD=2.31; 95% CI 2.50 to 2.11; P<0.001)
(Supplemental Digital Content 4A-F, http://links.lww.com/MD/
B173).
3.3. Subgroups of surgery
3.3.1. Orthopedic surgery. We found 15
studies[12,17,18,24–27,30,38,40,42,44,48,54,55] with a total of 1207
patients undergoing orthopedic surgery. In 12 tri-
als[12,18,24,26,27,30,38,42,44,48,54,55] including 1103 patients, (n=
529 cell salvage vs. n=574 control group) the use of a cell salvage
reduced the need of allogeneic RBC by a relative 57% (RR=0.43;
95% CI 0.36 to 0.51; P0.001; Fig. 3A). Ten stud-
ies[17,18,24,25,27,30,40,42,53,54] with 590 patients analyzed the
number of allogeneic blood units per patient. Comparison
of 293 patients in the cell salvage group and 297 patients in
the control group resulted in an average saving of 0.80 units
per patient (WDM=0.80; 95% CI 0.89 to 0.70; P<0.001)
(Fig. 3B). No statistical difference was observed
regarding infection (RR=0.61; 95% CI 0.22 to 1.67; P=0.33)
or mortality rate (RR=3.03; 95% CI 0.12 to 73.51; P=0.5)
(Fig. 3C, D).
Figure 1. Flow chart of literature search in the systemic review.
∗
Studies were
excluded if unwashed preoperative donated blood, unwashed cell salvaged
blood was retransfused, cell-salvage was used in all patients, acute
normovolemic hemodilution was applied, or retransfused blood has only
been ﬁltered but not washed.
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3.3.2. Cardiac surgery. We found 21
studies[9,14–16,20,22,23,28,29,32,33,35–37,41,43,46,47,50,51,53] with a to-
tal of 2249 patients undergoing cardiac surgery. Sixteen
trials[14–16,20,22,23,28,32,33,36,41,43,46,50,53,54] including 1056
patients in the cell salvage group and 867 control
patients showed an overall reduced exposure to allogeneic blood
cells by a relative 29% (RR=0.71; 95% CI 0.62 to 0.81;
P<0.001) (Fig. 4A). Analysis of 17
trials[9,14–16,20,22,23,28,32,35–37,41,46,50,51,53] involving 1109
patients assigned to the cell salvage group and 908 control
patients revealed an average saving of 0.65 units per patient
(RR=0.65; 95% CI 0.69 to 0.62; P<0.001) (Fig. 4B). The
use of cell salvage did neither affect infection (RR=0.94; 95%CI
0.61 to 1.46; P=0.79) nor mortality rate (RR=0.72; 95% CI
0.37 to 1.39; P=0.32) (Fig. 4C, D).
3.3.3. Vascular surgery. We found 6 studies[13,19,31,45,49,52]
with a total of 384 patients undergoing vascular surgery, of
which 5 trials[13,19,31,45,52] with 316 patients provided data on
the number of patients (n=154 cell salvage vs. n=162 control
group). The exposure to allogeneic RBC transfusion was reduced
Table 1
Studies included in meta-analysis.
Study Year Country Surgical discipline
Number of patients
in the control group
Number of patients in
the cell-saver group
Aghdaii et al[9] 2012 Iran Cardiac surgery 25 25
Bowley et al[10] 2006 Republic of South Africa Trauma surgery/massive bleeding 23 21
Cholette et al[11] 2013 United States Pediatric surgery 53 53
Cip et al[12] 2013 Austria Orthopedic surgery 75 76
Clagett et al[13] 1999 United States Vascular surgery 50 50
Dalrymple-Hay et al[14] 2001 United Kingdom Cardiac surgery 54 54
Dalrymple-Hay et al[15] 1999 United Kingdom Cardiac surgery 56 56
Damgaard et al[16] 2006 Denmark Cardiac surgery 30 30
Ekbäck et al[17] 1995 Sweden Orthopedic surgery 15 15
Elawad et al[18] 1991 Sweden Orthopedic surgery 20 19
Farrer et al[19] 1997 United Kingdom Vascular surgery 27 23
Goel et al[20] 2007 India Cardiac surgery 25 24
Jacobi et al[21] 1997 Germany Cancer surgery 12 12
Kelley-Patteson et al[52] 1993 United States Vascular surgery 18 18
Klein et al[22] 2008 United Kingdom Cardiac surgery 111 102
Koopman (a)[53] 1993 The Netherlands Cardiac surgery 20 20
Koopman (b)[54] 1993 The Netherlands Orthopedic surgery 30 30
Laub et al[23] 1993 United States Cardiac surgery 19 19
Liang et al[24] 2015 China Orthopedic surgery 55 55
Lisander and Nordwall[25] 1996 Sweden Orthopedic surgery 13 11
Lorentz et al[26] 1991 Germany Orthopedic surgery 15 16
McGill et al[28] 2002 United States Cardiac surgery 84 84
McShane et al[29] 1987 United States Cardiac surgery 21 20
Menges et al[30] 1992 Germany Orthopedic surgery 12 14
Mercer et al[31] 2004 United Kingdom Vascular surgery 41 40
Murphy et al[33] 2005 United Kingdom Cardiac surgery 31 30
Murphy et al[32] 2004 United Kingdom Cardiac surgery 97 99
Nicolai et al[34] 2004 United Kingdom Pediatric surgery 11 11
Niranjan et al[35] 2006 United Kingdom Cardiac surgery 40 40
Parrot et al[36] 1991 France Cardiac surgery 22 44
Perttilä et al[37] 1994 Finland Cardiac surgery 12 12
Rollo et al[38] 1995 United States Orthopedic surgery 78 35
Sankarankutty et al[39] 2006 Brazil Cancer surgery 19 22
Lukic-Sarkanovic et al[27] 2013 Serbia Orthopedic surgery 55 55
Savvidou et al[40] 2009 Greece Orthopedic surgery 25 25
Scrascia et al[41] 2012 Italy Cardiac surgery 17 17
Shenolikar et al[42] 1997 United Kingdom Orthopedic surgery 50 50
Sirvinskas et al[43] 2007 Lithuania Cardiac surgery 49 41
Slagis et al[44] 1991 United States Orthopedic surgery 51 102
Spark et al[45] 1997 United Kingdom Vascular surgery 27 23
Tempe et al[46] 1996 India Cardiac surgery 50 50
Tempe et al[47] 2001 India Cardiac surgery 20 20
Thomas et al[48] 2001 United Kingdom Orthopedic surgery 116 115
Thompson et al[49] 1990 United Kingdom Vascular surgery 34 33
Vermeijden et al[50] 2015 The Netherlands Cardiac surgery 177 364
Xie et al[51] 2015 China Cardiac surgery 69 72
Zhang et al[55] 2008 China Orthopedic surgery 20 20
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by a relative 45% in the cell salvage group (RR=0.55; 95% CI
0.44 to 0.68; P<0.001; Fig. 5A). Three studies[13,19,52] including
186 patients (n=91 cell salvage vs. n=95 control group)
provided data for the usage of RBC units that did not differ
signiﬁcantly (RR=0.04; 95% CI 0.11 to 0.19; P=0.59;
Fig. 5B). Infection rate was signiﬁcantly reduced in the cell
salvage group (n=169) compared with control group (n=179)
by relative 62% (RR=0.38; 95% CI 0.22 to 0.67; P<0.001;
Figure 2. Forest plot of cell salvage compared with control intervention in all types of surgery. (A) Number of patients exposed to allogeneic RBC, (B) number of
units of allogeneic RBC per patients, (C) infections, (D) mortality rate. RBC= red blood cell.
Figure 3. Forest plot of cell saver compared with no cell saver in orthopedic surgery. (A) Number of patients exposed to allogeneic RBC, (B) number of units of
allogeneic RBC per patients, (C) infections, (D) mortality rate. RBC= red blood cell.
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Fig. 5C). The use of a cell saver did not show statistically
signiﬁcant difference in mortality (RR=0.79; 95% CI 0.20 to
3.13; P=0.74; Fig. 5D).
3.3.4. Multiple trauma/massive transfusion. We found only
one trial[10] including 44 patients (n=21 cell salvage vs. n=23
control group) with multiple trauma. The use of cell salvage
resulted in an overall saving of allogeneic RBC by a relative 99%
(RR=1.00; 95% CI 0.92 to 1.09; P=1.00; Supplemental Digital
Content 5A, http://links.lww.com/MD/B173). In average 4.70
units (RR=4.70; 95% CI 8.01 to 1.39; P=0.005) of RBCs
per patient could be saved in the cell salvage group (Supplemental
Digital Content 5B, http://links.lww.com/MD/B173). Infection
and mortality rate did not vary between the two groups
(infection: RR=0.78; 95% CI 0.29 to 2.09; P=0.62; mortality:
RR=1.02; 95% CI 0.67 to 1.56; P=0.92; Supplemental Digital
Content 5C, D, http://links.lww.com/MD/B173).
3.3.5. Cancer surgery. We found 2 studies[21,39] that used cell
salvage including 65 participants undergoing cancer surgery. One
trial[21] addressed the number of patients exposed to allogeneic
blood transfusion (n=12 cell saver group vs. n=12 control
group), and revealed a reduced exposure by a relative of 25%
(RR=0.75; 95% CI 0.38 to 1.50; P=0.42; Supplemental Digital
Content 6A, http://links.lww.com/MD/B173). In average 1.21
units of RBCs (RR=1.21; 95% CI 2.27 to 0.16; P=0.02)
could be saved (Supplemental Digital Content 6B, http://links.
lww.com/MD/B173). None of the two studies reported infection
or mortality for either the cell salvage or control group.
3.3.6. Pediatric surgery. Two studies[11,34] used cell salvage of
which one study[34] assessed the number of patients (11 patients
per group) exposed to allogeneic RBC transfusion that was
reduced by a relative 78% (RR=0.22; 95% CI 0.07 to 0.66; P=
0.007; Supplemental Digital Content 7A, http://links.lww.com/
MD/B173). Both studies examined the number of blood units
applied per patient (n=56 cell salvage vs. n=56 control group).
In average, a reduction of 0.87 RBC units per patient could be
observed upon cell salvage usage (RR=0.87; 95% CI 1.16 to
0.57; P<0.001; Supplemental Digital Content 7B, http://links.
lww.com/MD/B173). One trial[11] reported the number of
infections and mortality in which 106 patients were equally
randomly distributed into the cell salvage or control group. The
use of cell salvage did not reduce infection (RR=1.13; 95% CI
0.47–2.69; P=0.79) or mortality rate (RR=3.00; 95% CI
0.32–27.93; P=0.33; Supplemental Digital Content 7C, D,
http://links.lww.com/MD/B173).
3.3.7. Transfusion “triggers” / thresholds. Of the 47 included
trials 22 studies[9,13–15,18,20–22,24,26–28,31,33,35,37,39,40,42,48,49,51]
reported the use of a transfusion protocol for allogeneic RBC
transfusion. Transfusion threshold did not vary between cell
salvage and control group. Cell salvaged blood was retransfused
at the end of surgery. The intra- and postoperative transfusion
trigger for hemoglobin (Hb) ranged from 7 to 10g/dL. Sixteen
trials reported an intraoperative transfusion threshold, 2
trials[13,37] reported an Hb transfusion threshold of 10.0g/dL,
4 trials[20,26,28,48] between 9.0 and 9.5g/dL, 4 trials[21,27,31,51]
between 8.0 and 8.9g/dL, 6 trials[9,15,22,24,32,40] of 7.0g/dL.
Eighteen trials reported a postoperative transfusion threshold, 5
trials[13–15,26,49] reported a Hb transfusion threshold of 10.0g/
dL, 3 trials[28,42,48] between 9.0 and 9.5g/dL, 7 tri-
als[18,21,22,27,35,39,51] between 8.0 and 8.9g/dL, 3 trials[24,33,40]
of 7.0g/dL, and 10 trials[9,13,16,19,20,28,33,36,40,49] transfused
patients when the hematocrit value was less than 30%.
3.3.8. Quality management and cost analysis. All included
studies did not provide sufﬁcient comparable data to either
estimate the quality of salved blood or to perform cost analysis
(see Supplemental Digital Content 8–9, http://links.lww.com/
MD/B173).
Figure 4. Forest plot of cell saver compared with no cell saver in cardiac surgery. (A) Number of patients exposed to allogeneic RBC, (B) number of units of
allogeneic RBC per patient, (C) infections, (D) mortality rate. RBC= red blood cell.
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4. Discussion
Patient blood management encompasses multiple blood-sparing
techniques that minimize the risk for blood loss and the need for
allogeneic RBC transfusion.[56] In this respect, cell salvage is an
important tool of blood conservation but is inconsistently used in
daily practice due to uncertainties about its efﬁciency.
The latest Cochrane meta-analysis of prospective trials was
published in 2010 and included 75 studies focusing on the ﬁeld
of cardiac, vascular, and orthopedic surgery that used both
washed and unwashed cell salvage reporting an overall
reduction by a relative 38%.[5] Recent studies, however,
demonstrated that the use of unwashed cell salvage negatively
affect recovery after surgery. Unwashed salvaged blood may be
enriched with inﬂammatory mediators,[57–59] ﬁbrin degradation
products[60,61] and interleukins[62,63] that exceed body’s own
circulating levels leading to enhanced coagulopathy, systemic
inﬂammation, or acute respiratory distress syndrome. Addi-
tionally, some concerns emerged during the last years upon the
observation that total drain output was shown to be
signiﬁcantly greater after unwashed salvaged blood retrans-
fusion during total knee arthroplasty compared with patients
receiving allogeneic transfusion only.[64–66] In this study, we
performed an up-dated meta-analysis of randomized controlled
trials focusing on washed salvage in which patients of all ages
were randomized either to washed cell salvaged or to a control
group scheduled for all types of surgery with a broad spectrum
of relevant clinical endpoints. Our search resulted in 8
additional trials published beyond 2010 and 10 trials with a
total of 1630 patients that were not included in the latest
Cochrane Analysis. We showed that the overall use of washed
cell salvaged blood reduces perioperative allogeneic RBC
transfusion exposure by a relative 39%with the most signiﬁcant
result in orthopedic surgery where the use of cell salvage reduced
the exposure by 57% in 15 trials. Thus, the overall consumption
decreased by 0.80 RBC units per patient. A recent observational
study including approximately 1.6 million patients revealed that
transfusion of a single unit allogeneic RBC already double the
risk for myocardial infarction and/or ischemic stroke.[4]
Notable, Rohde et al performed a systematic review and
meta-analysis including 7456 patients assigned either to a
restrictive or liberal transfusion practice. A restrictive transfu-
sion strategy with less RBC transfusion was associated with a
reduced risk of serious infections.[67] In accordance, our meta-
analysis demonstrated a reduced infection rate upon usage of
cell salvage reduced allogeneic RBC transfusion rate.
In cancer surgery, however, the use of cell salvage is
controversially debated and much reservation exists among
surgeons. Retransfusion may increase the risk of cancer
recurrence, while allogeneic RBC transfusion may also be
associated with increased risk of cancer recurrence. However,
a recent systematic review emphasizes that the use of a leucocyte
depletion ﬁlter enables the elimination of tumor cells from
blood–tumor cells mixture, whereas a standard ﬁlter did not.
Overall the study showed that the use of cell salvage in patients
having cancer surgery was not associated with a greater risk of
tumor dissemination or metastasis. However, caution must be
givenwhen tumor rupture occurs during surgery as washed blood
remained positive for tumor cells.[68] A statistically powered trial
is essentially needed to ﬁnally elucidate whether cell salvaged
blood or allogeneic RBC transfusion is superior in terms of cancer
recurrence.
To our knowledge no results of prospective randomized
controlled trials have been published in the last decade describing
the use of cell salvage within multiple trauma surgery. The
technique has not been widely accepted for trauma patients
undergoing urgent surgery because of various reasons. Firstly,
logistic issues exist for implementing an immediate auto-
transfusion protocol. In addition, trauma induced injuries persist
a high potential for infections and bacterial contamination.
However, our analysis of one trial including multiple traumata
surgeries conﬁrmed the beneﬁcial use of cell sever in that 4.70
units of blood could be saved per patient, thereby strongly
supporting it’s use within trauma patients. Cholette et al[11]
showed impressively, that cell saver blood can safely be stored at
the bedside for immediate transfusion for 24hours after
collection disclosing an additional opportunity to retransfuse
autologous blood. It would be of interest to conduct a
randomized controlled study that is statistically powered to
conﬁrm these results.
Till now, cell salvage is not widely used during cancer or
trauma surgery, however current evidence justify further
evaluation of its use in clinical studies.
Technical limitations generally restrict the use of cell salvage
for infants during surgery. Yet advancements and increasing
knowledge may allow volume-independent collection and
retransfusion of salvaged blood.[69] Our search revealed two
Figure 5. Forest plot of cell saver compared with no cell saver in vascular surgery. (A) Number of patients exposed to allogeneic RBC, (B) number of units of
allogeneic RBC per patient, (C) infections, (D) mortality rate. RBC= red blood cell.
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trials that support the use of cell salvage technique during
pediatric surgery. Analysis of 106 infants undergoing cardiac
surgery with cardiopulmonary bypass weighing less than or equal
to 20kg and 22 patients between 6 and 17 years undergoing
acetabulosplasty revealed a 5-fold less exposure to allogeneic
RBCs and 0.87 less RBC units per patient in the cell salvage group
compared with the control group. Thus, our analysis supports
and recommends the use of cell salvage during pediatric surgery.
Inappropriate allogeneic RBC transfusion may be associated
with increased morbidity and mortality. From the urgent need to
formulate common transfusion threshold the World Health
Assembly has endorsed PBM, requesting the World Health
Organization to provide its member states with training on the
safe, rational use of allogenic RBC transfusion and transfusion
alternatives (WHA63.12) in 2010.[70] In accordance with this
release we observed a change in transfusion practice in the trials
outlined in this study. Initially, we detected a broad transfusion
range between 7 and 10g/dL in studies published until 2005 that
became more restricted in the last decade with a transfusion
trigger ranging between 7 and 8g/dL. In most studies, transfusion
thresholds did not vary between the cell salvage and control
group. Due to the different beneﬁt-risk-ratio, we rather suggest
that salvaged blood should be routinely retransfused irrespective
of the Hb level. It is noteworthy, that in addition to a restrictive
transfusion policy an improvement in patient outcome (reduced
RBC transfusion rate, infection rate and length of hospital stay)
could be observed upon utilization of cell salvage within the
surgical setting. Our meta-analysis could not clarify whether the
use of cell salvage is associated with increased or decreased costs.
Three trials[10,16,22] observed no cost differences; one[48] reported
an increased cost investment for the use of cell salvage usage and
one[40] estimated reduced costs of 225 € per patient upon
retransfusion of salvaged blood. Thus, estimation of cost is
challenging as different parameters were deﬁned for cost
calculation.
With regard to the pooled analysis, some limitations must be
taken into account. In our meta-analysis we found that most of
the studies were of limited methodological quality and risk of bias
could not be fully judged in any of the included trials. The
majority of the included trials did not provide detailed
information about procedure or blinding. Analyses of individual
trials suggest that some effect sizes were overestimated, for
example participants with long hospitalization were excluded
from the analysis.[54] Investigation of publication bias by
generating funnel plots showed no obvious deviations from
symmetry excluding the possibility of potential publication bias.
However, a tendency may exist to publish more likely trials in
favor of the studied intervention and may challenge the
signiﬁcance of the meta-analysis presented in this study.[71]
The times of re-infusion of autologous RBCs differed widely from
the time point of surgery, to skin closure up to 6hours post-
surgery or were not described at all and might affect study
outcome.
5. Conclusion
On the basis of this meta-analysis, washed cell salvage is
efﬁcacious in reducing the need for allogeneic RBC transfusion in
surgery and even in decreasing the risk of infection. Thus, we
recommend the use of cell salvage for surgery in which blood loss
is a concern. However, the methodical qualities of the presented
study are poor in quality, and further large randomized
prospective trials are still needed.
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